Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Status:
Enrolling by invitation
Trial end date:
2027-07-02
Target enrollment:
Participant gender:
Summary
Multicenter, open-label, prospective treatment protocol that provides continued access to
ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from
treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying
disease within their region.